Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells by Bunde, Torsten et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 201, No. 7, April 4, 2005 1031–1036 www.jem.org/cgi/doi/10.1084/jem.20042384
 
BRIEF DEFINITIVE REPORT
 
1031
 
Protection from cytomegalovirus after 
transplantation is correlated with immediate 
early 1–speciﬁc CD8 T cells
 
Torsten Bunde,
 
1 
 
Alexander Kirchner,
 
1 
 
Bodo Hoffmeister,
 
1 
 
Dirk Habedank,
 
3
 
Roland Hetzer,
 
3 
 
Georgy Cherepnev,
 
1 
 
Susanna Proesch,
 
2 
 
Petra Reinke,
 
4
 
Hans-Dieter Volk,
 
1 
 
Hans Lehmkuhl,
 
3 
 
and Florian Kern
 
1
 
1
 
Institut für Medizinische Immunologie and 
 
2
 
Institut für Virologie, Charité, Universitätsmedizin Berlin, Campus Mitte, 
10098 Berlin, Germany
 
3
 
Deutsches Herzzentrum, 13353 Berlin, Germany
 
4
 
Medizinische Klinik mit Schwerpunkt Nephrologie und internistische Intensivmedizin, Charité, Campus Virchow-Klinikum, 
13353 Berlin, Germany
 
T cells are crucial for the control of cytomegalovirus (CMV) in infected individuals. Although 
CMV-specific T cells can be quantified by various methods, clear correlates of protection 
from CMV disease have not been defined. However, responses to the pp65 protein are 
believed to play an important role. Here, the proportions of interferon 
 
 
 
–producing T cells 
following ex vivo activation with pools of overlapping peptides representing the pp65 and 
immediate early (IE)-1 proteins were determined at multiple time points and related to the 
development of CMV disease in 27 heart and lung transplant recipients. Frequencies of 
IE-1–specific CD8 T cells above 0.2 and 0.4% at day 0 and 2 wk, respectively, or 0.4% at 
any time during the first months discriminated patients who did not develop CMV disease 
from patients at risk, 50–60% of whom developed CMV disease. No similar distinction 
between risk groups was possible based on pp65-specific CD8 or CD4 T cell responses. 
Remarkably, CMV disease developed exclusively in patients with a dominant pp65-specific 
CD8 T cell response. In conclusion, high frequencies of IE-1 but not pp65-specific CD8 
T cells correlate with protection from CMV disease. These results have important implications 
for monitoring T cell responses, adoptive cell therapy, and vaccine design.
 
CMV reactivation is frequent in virus carriers
(1); however, CMV disease occurs only if the
T cell response is compromised (2, 3). Because
T cells are instrumental in graft rejection,
drugs suppressing the T cell response are re-
quired after transplantation. They do not as
such cause CMV disease; however, they facilitate
this life-threatening complication (2). There-
fore, prophylactic and/or preemptive antiviral
treatment is often administered (4). CTL re-
sponses have been known to correlate with re-
covery from CMV disease in bone marrow
transplant (BMT) recipients since 1982 (3).
In murine CMV infection (BALB/c mice),
the immediate early (IE) protein, pp89, was
known to be an important CTL target protein
already in the late 1980’s, and CTL responses
against pp89 were shown to mediate protec-
tion in several studies (5, 6). IE-1–specific T cell
responses in CMV-infected humans were de-
scribed as early as 1991 (7). However, a study
in fully immune reconstituted BMT recipi-
ents in 1994 revealed that their CMV-specific
CTLs were able to kill CMV-infected fibro-
blasts even if preincubated with actinomycin
D (an inhibitor of CMV replication), and,
therefore, these CTLs were believed to be di-
rected at virion proteins such as pp65 (8). Al-
though actinomycin D permits the synthesis of
IE gene products (9), IE-1 was no longer con-
sidered a relevant target, because reports had
suggested that it was not efficiently presented
on class I MHC after infection (10). By con-
trast, virion proteins were known to be pre-
sented even in the absence of viral replication
(11), and additionally, pp65 itself was found to
interfere with IE-1 presentation (12). As a result,
research in this field concentrated on pp65 (13,
14). The interest in IE-1 as a T cell target in
human CMV infection was not revived until
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1999, when IE-1–specific CD8 T cells were described to oc-
cur in infected individuals at frequencies at least comparable
to those of pp65-specific CD8 T cells (15). To date, both
pp65 and IE-1 are considered dominant T cell targets (6).
Some recent studies confirmed a positive correlation be-
tween immune reconstitution and rising numbers of pp65-
specific T cells (16–18). Unfortunately, IE-1–specific CD8
T cells were not included in these investigations, and, after
BMT, any parameter indicating the return or advent of
CMV-specific T cell immunity would be expected to cor-
relate with a lower incidence of CMV disease to some de-
gree (3). Detection of antigen-specific T cells in this study
relies on the intracellular accumulation of the effector cy-
tokine, IFN-
 
 
 
, in functional but secretion-inhibited T
cells. IFN-
 
  
 
induction was achieved by ex vivo stimulation
with peptide pools representing all possible CD4 and CD8
T cell epitopes in pp65 and IE-1 (19, 20). CD4 and CD8 T
cell responses to both proteins were measured at multiple
time points in 27 heart and lung transplant recipients and
correlated with clinical data. Our study clearly shows that
dominance and magnitude of the IE-1– but not the pp65-
specific CD8 T cell response correlate with protection
from CMV disease.
 
RESULTS AND DISCUSSION
 
To assess whether the presence and/or magnitude of
CMV-specific T cell responses had an influence on the de-
velopment of CMV-related complications in 23 heart and 4
lung transplant recipients, responses to IE-1 and pp65 were
measured beginning at the time of transplantation and end-
ing between 3 mo and 2 yr after it (monitoring period).
Clinical data evaluation always included the complete moni-
toring period but at least 1 yr after transplantation. No signif-
icant effects of donor CMV serostatus and drug regimen on
the development of pp65 antigenemia and CMV disease
were elicited.
In all patients with a CD4 T cell response to pp65
(“CD4/pp65 response”), a CD8 T cell response to pp65
(“CD8/pp65 response”) or a CD8 T cell response to IE-1
(“CD8/IE-1 response”), the reponses were consistently found
over time. By contrast, the CD4 T cell response to IE-1
(“CD4/IE-1 response”) was frequently undetectable during
the first 100 d and therefore not included in further data
analysis. Overall, the response distribution was in keeping with
previous results (Table I; references 19 and 21).
Initial data inspection suggested that unlike patients who
developed CMV disease (“Disease-Group”), those who did
not (“No-Disease-Group”) frequently had high CD8 T cell
responses to IE-1 (Fig. 1). Based on clinical considerations,
the following approximated time points were chosen for as-
sessing T cell responses: day 0 (median: 0 d, range: 0–4 d,
 
n 
 
  
 
27); 2 wk (median: 14 d, range: 11–19 d, 
 
n 
 
  
 
27); 1 mo
(median: 29 d, range: 24–37 d, 
 
n 
 
  
 
27); and 3–4 mo (median
95 d, range: 89–117 d, 
 
n 
 
  
 
26), after which CMV disease is
rare. Notably, one out of nine patients (11%) developed
CMV disease within 2 wk, four out of nine (44%) within the
first month, eight out of nine (88%) within 3–4 mo, and
only one patient (11%) later than that. Therefore, the most
 
Table I.
 
Global CD4 and CD8 T cell response patterns
 
Patients responding to
Responding T cell subset pp65 pool IE-1 pool
 
CD4 T cells 23 (85%) 11 (41%)
 
a
 
Median frequencies (range) day 0 0.27 (0.02–17.23) 0.04 (0.01–0.16)
In % of total CD4 T cells 3–4 mo 0.28 (0.03–16.89) 0.08 (0.05–0.19)
Response was dominant in
 
b
 
22 0
CD8 T cells 27 (100%) 20 (74%)
Median frequencies (range) day 0 0.44 (0.02–8.06) 0.97 (0.01–10.81)
In % of total CD8 T cells 3–4 mo 0.55 (0.04–13.01) 1.05 (0.03–15.47)
Response was dominant in
 
b
 
17 9
 
a
 
In most donors, this response was not observed at all time points.
 
b
 
In one case, no clear dominance of either response was observed.
Figure 1. High frequencies of IE-1–specific CD8 T cells are associ-
ated with protection from CMV disease. Dot plots show responses to 
the CMV pp65 and IE-1 peptide pools in two representative patients, one 
of whom developed CMV disease on day 39 after transplantation (left). 
CD8 T cells are shown (IFN-   events highlighted in black). The relative 
frequencies of IFN-   events are indicated. Axes show log fluorescence. 
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interesting time points for predicting the risk of CMV dis-
ease would have been day 0 and 2 wk (Fig. 2).
Apart from their magnitude (relative frequencies), the re-
lationship between the responses was considered. A response
was considered dominant in a patient if it was the biggest re-
sponse (by relative frequencies) at a majority of time points.
The CD8/pp65 response was the most dominant overall
(56%), followed by the CD8/IE-1 response (26%), and the
CD4/pp65 response (19%). Considering the CD8 compart-
ment alone, CD8/pp65 or CD8/IE-1 responses dominant at
day 0 remained so for at least 3 mo in 25 out of 27 patients
(93%), whereas changes of the dominant response within the
CD4 compartment were not observed at any time. Interest-
ingly, 8 out of 15 patients with a dominant CD8/pp65 re-
sponse at day 0 developed CMV disease but only 1 out of 12
of the remaining patients did (P 
 
  
 
0.05; Fischer’s exact test
[FET]). Patients with no CD4 response to one of the pro-
teins or both and patients with no CD8/IE-1 response
seemed to develop CMV disease more often than the re-
maining patients (not statistically significant).
Nonparametric longitudinal analysis (22) of the CD8/
pp65, CD8/IE-1, and CD4/pp65 responses between day 0
and 3–4 mo was performed including the factors, time, and
group (CMV disease or not). Although time had no signifi-
cant effect on any parameter, the CD8/IE-1 response (but
not the other responses) was significantly different in the two
groups (P 
 
  
 
0.00487, with P adjusted for multiple [i.e.,
three] end points 
 
  
 
0.01461; Fig. 2, A–C), indicating that
this was the only relevant parameter for discrimination be-
tween the groups. Therefore, receiver operating characteris-
tics (ROC) analysis (23) was used to identify cut-off levels at
day 0 or 2 wk, CD8/IE-1 responses above or below which
would indicate a decreased or increased risk of CMV disease,
respectively (Fig. 3, A and B). Interestingly, 100% (9 out of
9) of patients whose CD8/IE-1 response exceeded 0.2% at
day 0 remained free of CMV disease compared with only
50% (9 out of 18) of the patients with lower frequencies
(P 
 
  
 
0.012, FET; sensitivity 
 
  
 
50%, specificity 
 
  
 
100%,
positive predictive value 
 
  
 
100%, and negative predictive
value 
 
  
 
50%). Identical results were obtained for a threshold
of 0.4% at 2 wk. Moreover, 100% (12 out of 12) of patients
whose CD8/IE-1 response exceeded 0.4% at any time dur-
ing the first month remained free of CMV disease compared
with only 40% (6 out of 15) with a lower maximum re-
sponse (P 
 
  
 
0.001 FET; sensitivity 
 
 
 
 66.7%, specificity 
 
 
 
100%, positive predictive value 
 
  
 
100%; and negative pre-
dictive value 
 
  
 
60%; Fig. 3 C). Importantly, IE-1 is the first
protein expressed upon CMV reactivation (24), and as a re-
sult, IE-1–specific T cells should be the first to be activated
and drawn to sites of replication. Notably, in monocytic pre-
cursor cells, which are known to harbor latent CMV, repli-
cation is arrested before early-phase proteins are made (24,
25). Therefore, they express IE products only and might be
recognized (and killed) by IE-1– but not pp65-specific CTL.
These cells are known to shuttle CMV to endothelia where
they mature, become permissive to CMV replication, and
eventually pass on the infectious virus (26). This “feeding”
mechanism can probably be intercepted by IE-1–specific but
not pp65-specific T cells, which could be one reason why
high levels of IE-1–specific CD8 T cells are associated with
protection from CMV disease.
There was no statistical association between pp65 anti-
genemia occurring during the first 3–4 mo and the presence
and/or magnitude of any of the measured T cell responses.
Figure 2. Median frequencies of IE-1–specific CD8 T cells early 
after transplantation are higher in patients who do not develop CMV 
disease. CD4 and CD8 T cell responses to the CMV IE-1 and pp65 peptide 
pools were measured in 27 transplant recipients at specific time points 
using intracellular IFN-  staining. (A) The results for IE-1–specific CD8 T cells, 
(B) the results for pp65-specific CD8 T cells, and (C) the results for pp65-
specific CD4 T cells. In each panel, the results are divided by clinical group 
(CMV-disease or not). Box plots show the responses at the indicated time 
points (median, 25th and 75th percentiles, and extreme values). Nonpara-
metric longitudinal analysis was performed using SAS software (p-values 
are given for differences between the groups). A global significance level of 
0.05 is maintained if P   0.0166 for each of three tested end points. 
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However, in all patients who had CMV disease, this coin-
cided with their first pp65 antigenemia (tested at least weekly
during hospital stays or at each visit). Late pp65 antigenemia
(after day 100) occurred in only six patients and was not
linked to CMV disease.
Interestingly, in 15 patients the CD8/IE-1 responses
were below the above described threshold levels for the re-
sponse at day 0 or 2 wk, or the maximum response during
the first month; however, 6 out of these 15 did not develop
CMV disease, indicating that factors apart from the magni-
tude of the CD8/IE-1 response were related to protection.
In this regard, it appeared of particular interest to investigate
if patients had a lower risk of developing CMV disease if
they recognized a greater number of epitopes. Although all
15 patients had a CD8/pp65 response (13 of which had been
mapped), only 12 had a CD4/pp65 response (9 of which had
been mapped). The CD8/IE-1 response had been mapped
only in patients with a high response, who were not in-
cluded in this group. In fact, the median number of CD4
epitopes recognized in pp65 was two in patients who did not
develop CMV-disease (range 0–3) compared with one in pa-
tients who developed CMV disease (range 0–1); however,
the difference was statistically not significant (P 
 
  
 
0.232,
Mann-Whitney U test [MWU]). It was interesting, how-
ever, that four out of six patients who remained free of
CMV disease recognized two or more CD4 T cell epitopes
in pp65, but none of the patients who developed CMV dis-
ease did (P 
 
  
 
0.061, cross-table analysis using FET). At least,
this tendency suggested that recognition of several CD4
pp65 epitopes may also be related to protection, which will
be investigated in future studies. Meanwhile, there was no
difference between the groups with regard to the numbers of
CD8 epitopes or the sum of CD4 and CD8 epitopes recog-
nized in pp65 (P 
 
  
 
0.881 and P 
 
  
 
0.624, respectively,
MWU). The T cell responses mapped in this patient cohort
recognized known dominant epitopes including the CD8
epitopes pp65
 
495–503 
 
(NLVPMVATV, presented by HLA-
A2) and IE-1
 
309–317 
 
(CRVLCCYVL, presented by HLA-B7;
reference 6), the CD4 epitope pp65
 
365–379 
 
(EHPTFTSQY-
RIQGKL, presented by HLA-DR11; reference 21), and
others (6). Recognition of these determinants indicated that
mutations of IE-1 or pp65 in the clinical strains infecting our
patients did not play a significant role for this study.
Results from adoptive transfer studies have demonstrated
that CD4 T cells are essential for a lasting immune response
against CMV (27). Although our data suggest that the
breadth of the CD4/pp65 response may play a role in pro-
tection from CMV disease, we were unable to define critical
threshold levels for the frequencies of pp65-specific CD4 T
cells at particular time points. With regard to CD8 T cells,
however, our results indicate that observing the frequencies
of IE-1–specific CD8 T cells early after transplantation
might be useful for identifying risk groups in terms of CMV
disease. Our findings clearly challenge the paradigm that
pp65 is the most important protein recognized by CD8 T
cells in human CMV infection. By contrast, the relevance of
the IE-1 protein as a T cell target protein is underscored.
Moreover, that CMV disease developed only in individuals
with a dominant CD8/pp65 response shows that dominance
by frequencies does not necessarily indicate relevance in
terms of protection. In conclusion, our study demonstrates
that the definition of protective levels based on the frequen-
cies of antigen-specific peripheral blood T cells is a realistic
possibility for the future. Looking at the right specificities,
however, will be crucial.
 
MATERIALS AND METHODS
 
Patients and medication.
 
After written informed consent, 27 patients
were enrolled (21 male and 6 female), including 23 heart and 4 lung trans-
plant recipients, with ages ranging from 32 to 67 yr (median 51). Primary
disease included cardiomyopathy (15), coronary heart disease (7), malforma-
tion (1), primary pulmonary hypertension (2), and 
 
 
 
-1-antitrypsin-defi-
ciency (2). Table II shows a summary of CMV-related parameters. Initial
maintenance-immunosuppressive medication included cyclosporin A
(CsA), prednisolone (Pred), and azathioprine (Aza) in 16 patients and CsA,
Figure 3. The magnitude of the CD8/IE-1 response identifies patients 
who will not develop CMV disease. ROC analysis was performed to define 
optimum thresholds of the CD8/IE-1 response (relative frequency) that 
would discriminate between patients who did or did not develop CMV 
disease. Panels show ROC curves for the response at day 0 (A), 2 wk (B), and 
for the maximum response during the first month (C). The area under the 
curve (AUC) for the CD8/IE-1 response graph is indicated. Graphs for the 
CD8/pp65 and CD4/pp65 responses are shown for reference. 
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Pred, and mycophenolate mofetil (MMF) in 11 patients. 7 patients were
switched from Aza to MMF later. Immunosuppressive induction therapy
included methylprednisolone (Mpred) and ATG bolus in all patients. Acute
graft rejection was treated with high dose intravenous Mpred or ATG. Re-
cipients of CMV-seropositive lung transplants received oral ganciclovir
(GCV) during the first 3 mo (
 
n 
 
  
 
4). Patients with CMV reactivation (pp65
antigenemia) were treated with intravenous GCV until pp65 antigen was
negative followed by oral GCV for 4 wk. Standard comedication included
antibiotics, anti-hypertensive drugs, and diuretics. The study was approved
by the Charité Internal Review Board (Ethikkomission Charité Mitte).
 
Monitoring parameters and period.
 
Monitoring began immediately
before transplantation (day 0) in four cases within 2–4 d of transplantation
and was performed weekly during hospitalization and biweekly or less fre-
quently in out-patients. In 27 patients, pp65- and IE-1–specific responses
were monitored for 2 mo or more, in 26 patients for 3 mo or more, and in
18 patients for more than 1 yr. The median number of monitoring time
points per patient was 14 (range: 7–21). Other parameters determined at
each visit included pp65 antigenemia by immune fluorescence, CsA levels,
echocardiography, electrocardiogram, and standard blood chemistry.
 
PBMC preparation and ex vivo IFN-
 
  
 
induction assay.
 
After prepa-
ration from citrated blood (Ficoll-Paque; Amersham Biosciences) PBMCs
were washed twice in sterile PBS (GIBCO BRL) and resuspended in RPMI
1640 medium (Biochrome) containing 10% (vol/vol) heat-inactivated FCS
(Biochrome), 2 mM 
 
L
 
-glutamine (Biochrome), and 100 IU of penicillin/
streptomycin (Biochrome). Cells were incubated in bulk overnight for 16 h
at 37
 
 
 
C in a humidified 5% CO
 
2 
 
atmosphere in loosely covered Falcon
50-ml blue-cap conical tubes (BD Biosciences). Next, 400 
 
 
 
l of the vol-
ume-adjusted cell suspension was transferred to Falcon 2025 tubes (BD Bio-
sciences). The maximum number of cells per assay tube was 2 
 
  
 
10
 
6
 
. Imme-
diately, 100 
 
 
 
l RPMI/FCS medium containing single peptides or peptide
pool (4 
 
 
 
l of stock solutions) was added. At 2 h, 500 
 
 
 
l RPMI/FCS me-
dium was added containing 20 
 
 
 
g/ml brefeldin A (BFA; Sigma-Aldrich),
corresponding to 2 
 
 
 
l BFA stock solution. Final concentrations of (each)
peptide and BFA were 1 
 
 
 
g/ml and 10 
 
 
 
g/ml, respectively. Unstimulated
control samples were run in parallel (4 
 
 
 
l DMSO instead of peptide stock
solution). At 6 h, cells were washed with 3 ml ice-cold PBS (430 g for 8
min at 4
 
 
 
C), resuspended in PBS containing 1 mM EDTA (Sigma-Aldrich),
incubated in a 37
 
 
 
C water bath for 10 min to detach adherent cells, spun
down (430 g for 8 min at 4
 
 
 
C), and carefully vortexed for 30 s. Cells were
then washed with PBS containing 0.5% bovine serum albumin and 0.1%
(wt/vol) Na-azide (wash buffer), the supernatant was removed, and tubes
were blotted dry. For permeabilization/fixation (one step), the pellets were
resuspended in 1 ml of double-concentrated FACS-Lysing Solution (BD
Biosciences) containing 0.05% (vol/vol) of Tween 20 (Sigma-Aldrich; ref-
erence 21), incubated for 10 min (in the dark at room temperature), washed,
resuspended, stained with monoclonal antibodies (100 
 
 
 
l total volume at
4
 
 
 
C for 30 min in the dark), and washed once more before analysis.
 
Antibodies.
 
FITC-conjugated anti–INF-
 
 
 
, PE-conjugated anti-CD69,
PerCP-conjugated anti-CD3 and allophycocyanin-conjugated anti-CD8
and anti-CD4 were purchased from BD Biosciences.
 
Peptides.
 
Standard 15–amino acid peptides (11 overlaps) spanning the
CMV IE-1 and pp65 proteins (Swiss-Prot Nr. P14332 and P06725, respec-
tively) were purchased (Jerini Biotools). Quality control included mass
spectroscopy and HPLC (purity 
 
 
 
70%). Stock solutions (8 or 80 mg/ml in
DMSO) were stored at 
 
 
 
80
 
 
 
C.
 
Flow cytometry and data analysis.
 
Per sample, 150,000–250,000
events in the FSC/SSC lymphocyte gate were acquired on a FACS Calibur
flow cytometer (Becton Dickinson). For data analysis (CELLQuest soft-
ware; Becton Dickinson), CD3
 
 
 
/CD8
 
  
 
or CD3
 
 
 
/CD3
 
  
 
events were dis-
played in a CD69 versus IFN-
 
  
 
dot plot. CD8
 
  
 
or CD8
 
 
 
/INF-
 
 
 
  
 
cells
were expressed as a percent of the respective reference population. CD8
 
 
 
CD3 T cells were used as surrogate for CD4 T cells, which is an acceptable
approximation for this type of study (21). Positive events in the correspond-
ing regions in unstimulated samples were subtracted. The assessment of re-
sponses was previously described in more detail (19, 21).
 
Epitope identification.
 
Epitope mapping was performed based on the ex
vivo IFN-
 
  
 
induction assay described above using crossover pools of pp65
and IE-1 peptides. All identified epitopes were confirmed using individual
peptides for stimulation as previously described in more detail (15, 21).
 
Clinical data collection.
 
Complete clinical data analysis covered at least
1 yr and always exceeded the monitoring period. Diagnosis of CMV disease
required at least pp65 antigenemia (
 
 
 
2 positive cells/200,000), neutrope-
nia, and otherwise unexplained fever. Additional criteria included positive
chest radiographs, positive organ biopsy, or other relevant laboratory results
suggestive of specific organ involvement.
 
Statistics.
 
SPSS 11.0 (SPSS Inc.) and SAS 9.0 software (SAS Institute)
were used. Differences between two unpaired groups were analyzed using
the MWU. ROC analysis was used to define cut-off values (22). FET was
used for cross-table analysis. Nonparametric, factorial analysis of longitudi-
nal data was performed using the corresponding SAS-module according to
Brunner et al. (23). Where applicable, P was adjusted for multiple end-
points (Bonferroni adjustment).
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